Bleeding Patterns During Prophylaxis with a Full-Length Pegylated Recombinant Factor VIII (Bax 855) with Extended Half-Life in Hemophilia A

被引：0
|
作者：
Konkle, B. A. [1 ,2 ]
Stasyshn, O. [3 ]
Wynn, T. T. [4 ]
Manco-Johnson, M. J. [5 ]
Gruppo, R. [6 ]
Chowdary, P. [7 ,8 ]
Komrska, V. [9 ]
Griskevicius, L. [10 ]
Eyster, M. E. [11 ]
Chojnowski, K. [12 ]
Engl, W. [13 ]
Patrone, L. [14 ]
Abbuehl, B. [13 ]
机构：
[1] Bloodworks Northwest, Seattle, WA USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Ukraine Acad Med Sci, Lvov, Ukraine
[4] Univ Florida, Coll Med, Gainesville, FL USA
[5] Univ Colorado, Sch Med, Aurora, CO USA
[6] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
[7] Royal Free Hosp, KD Haemophilia Ctr, Pond St, London NW3 2QG, England
[8] Royal Free Hosp, Thrombosis Unit, Pond St, London NW3 2QG, England
[9] Univ Hosp Motol, Prague, Czech Republic
[10] Vilnius Univ Hosp Santariskiu Klinikos, Vilnius, Lithuania
[11] Penn State Hershey Med Ctr, Hershey, PA USA
[12] Med Univ Lodz, Lodz, Poland
[13] Baxalta Innovat GmbH, Vienna, Austria
[14] Baxalta US Inc, Westlake Village, CA USA
来源：
HAEMOPHILIA | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P128
引用
收藏
页码：99 / 100
页数：2
相关论文
共 50 条
  • [41] Interaction of BAX 855, a pegylated full-length recombinant FVIII, with the FVIII clearance receptor LRP
    Schrenk, G.
    Billwein, M.
    Schaedler, M.
    Turecek, P. L.
    Scheiflinger, F.
    HAEMOPHILIA, 2014, 20 : 63 - 64
  • [42] ECONOMIC EVALUATION OF RECOMBINANT EXTENDED HALF-LIFE FACTOR VIII PROPHYLAXIS FOR PEOPLE WITH HEMOPHILIA A - A SYSTEMATIC REVIEW (COSTIVE PROJECT)
    Araujo, M. S.
    Camelo, R. M.
    Cedro, V. Q. M.
    Dos Santos, B. R. A.
    Azevedo, P. S.
    Pereira, A. C.
    HAEMOPHILIA, 2023, 29 : 53 - 53
  • [43] Response to Gringeri etal.: "recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis - new insight provided by pharmacokinetic modelling'
    Shapiro, A. D.
    Li, S.
    HAEMOPHILIA, 2015, 21 (06) : E489 - E492
  • [44] A phase 1 study of safety and pharmacokinetics (pk) of bax 855, a longer acting pegylated full-length recombinant factor VIII (PEG-RFVIII), in patients (pts) with severe hemophilia A
    Bevan, D.
    Conlan, M.
    Mant, T.
    Lissitchkov, T.
    Kazmi, R.
    Chowdary, P.
    Langer, F.
    Shima, M.
    Fukutake, K.
    Singer, J.
    Grigorian, A.
    Ewenstein, B.
    Wong, W. Y.
    HAEMOPHILIA, 2013, 19 : 41 - 41
  • [45] Extended half-life recombinant factor VIII treatment of hemophilia A in Brazil: an expert consensus statement
    Ozelo, Margareth Castro
    Antunes, Sandra Vallin
    Villaca, Paula Ribeiro
    Oliveira, Luciana Correa
    Pinto, Ieda Solange
    Lorenzato, Claudia Santos
    Prezotti, Alessandra Nunes Loureiro
    Picoli, Renato Mantelli
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 (01) : 36 - 41
  • [46] Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations (vol 106, pg 704, 2017)
    Nogami, Keiji
    Shima, Midori
    Fukutake, Katsuyuki
    Fujii, Teruhisa
    Taki, Masashi
    Matsushita, Tadashi
    Higasa, Satoshi
    Sato, Tetsuji
    Sakai, Michio
    Arai, Morio
    Uchikawa, Haruhiko
    Engl, Werner
    Abbuehl, Brigitt
    Konkle, Barbara A.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (01) : 123 - 124
  • [47] PHARMACOKINETIC DRUG EVALUATION OF STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII IN PATIENTS WITH HEMOPHILIA A
    Lopez-Jaime, F-J
    Perez-Raya, M.
    Doblas-Marquez, A.
    Martin-Tellez, S.
    Mena-Santano, A-M
    Munoz-Lopez, F-D
    HAEMOPHILIA, 2021, 27 : 107 - 107
  • [48] N8-GP: A new extended half-life recombinant factor VIII product for hemophilia A
    Chowdary, Pratima
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 : 3 - 4
  • [49] Switch to extended half-life recombinant factor VIII FC in severe hemophilia A patients under prophylaxis. Experience in one centre
    Jimenez, R.
    Nunez, R.
    Jimenez, P.
    Rodriguez-Martorell, F. J.
    Perez-Simon, J. A.
    HAEMOPHILIA, 2018, 24 : 117 - 117
  • [50] Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
    Reding, Mark T.
    Lalezari, Shadan
    Kenet, Gili
    Di Minno, Giovanni
    Ducore, Jonathan
    Solms, Alexander
    Shah, Anita
    Holme, Pal Andre
    Poulsen, Lone H.
    Meijer, Karina
    Simpson, Mindy
    Mancuso, Maria Elisa
    DRUGS IN R&D, 2024, 24 (03) : 359 - 381
12345